Navigation Links
Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
Date:12/1/2008

e to become or remain profitable; Vanda's inability to obtain the capital necessary to fund its research and development activities; Vanda's failure to identify or obtain rights to new product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the quarter ended September 30, 2008 (File No. 000-51863). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

(1) Rajaratnam, Shantha M.W.; et al. "Melatonin agonist ta
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
3. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
4. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
5. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
6. CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease
7. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
8. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
9. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
10. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
11. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... OTTAWA , April 23, 2015 /CNW/ - Health ... oral ibuprofen products to update the safety information regarding ... attack and stroke) when these products are used at ... increases with dose and duration of use. ... pain and fever relief, and to reduce inflammation. The ...
(Date:4/23/2015)... Apr. 23, 2015 Surna, Inc. (OTCQB: SRNA), ... state-of-the art equipment and systems for controlled environment ... cannabis cultivation, will host a shareholder conference call ... 2015, at 4:15 PM Eastern Standard Time/1:15 PM ... call will be listen-in only, but will include ...
(Date:4/23/2015)... 23, 2015  Hill-Rom Holdings, Inc., (NYSE: HRC ... at the Deutsche Bank 40 th Annual Health ... EDT. You are invited to listen to ... http://ir.hill-rom.com/events.cfm or access it directly at http://edge.media-server.com/m/p/yvym8uoy ... available one hour after conclusion of the live event ...
Breaking Medicine Technology:Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 2Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 3Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 4Surna, Inc. Announces Shareholder Conference Call 2Surna, Inc. Announces Shareholder Conference Call 3
... PRINCETON, N.J., Feb. 1, 2011 Soligenix, Inc. (OTC ... Company), a late-stage biopharmaceutical company, announced today that it ... President and Chief Medical Officer. Dr. Horgan is a ... and experience in the care of patients with inflammatory ...
... AssureRx Health, Inc. today announced the appointments of two ... Donald R. Wright, Jr. has been appointed as executive ... Bellano as senior vice president, sales & commercial programs. ... of AssureRx,s pharmacogenetic test, GeneSightRx®, and the blueprint ...
Cached Medicine Technology:Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 2Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 3Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 4AssureRx Appoints Senior Executives in Key Roles to Drive Company Growth 2AssureRx Appoints Senior Executives in Key Roles to Drive Company Growth 3
(Date:4/24/2015)... Vancouver, BC (PRWEB) April 24, 2015 ... Albert Yuzpe, Olive Fertility co-founder and co-director, has been ... Fertility Preservation at the Evening of Hope Gala. ... to recognize Dr. Albert Yuzpe, who has been at ... past 43 years,” says Jessica Séguin, Executive Director of ...
(Date:4/24/2015)... April 24, 2015 National Access ... and legal access to medical cannabis, is taking a ... supported when advising patients. , NAC is the first ... With a $250,000 grant, NAC will be providing 300 ... "Our goal is to help Canadians gain safe and ...
(Date:4/24/2015)... April 24, 2015 Telematics Berlin is ... automakers, tier 1 & 2 suppliers, content providers, associations ... players in the value chain, see them converge in ... not only hear from those companies currently at the ... future partners. Working on customer centric products, ParkTAG are ...
(Date:4/24/2015)... PURE Solutions, a leader in allergy travel ... Network), a highly respected education, advocacy and community out-reach ... information for a special allergy travel section ... goal for both organizations is to “make lives better” ... with asthma and allergies and by finding effective ways ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 ProTube Outro is ... Pro X video editors. ProTube Outro allows editors to ... 5 video drop zones. Position, scale, and rotate pictures/videos, ... ProTube Outro uses simple borders and shadows for a ... exclusive plugin. , ProTube Outro comes packed with over 30 ...
Breaking Medicine News(10 mins):Health News:Olive Fertility Centre Co-founder, Dr Al Yuzpe, Recognized as a Pioneer in Fertility Preservation 2Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2Health News:Telematics Berlin 2015’s inaugural European Automotive Start-Up Competition 2Health News:Telematics Berlin 2015’s inaugural European Automotive Start-Up Competition 3Health News:PURE Solutions Partners with Allergy and Asthma Network to Provide Allergy Travel Tips 2Health News:Pixel Film Studios, FCPX Plugin Developer Announced the Release of Protube Outro, Outro Screen Templates for Final Cut Pro X 2
... sexually transmitted infections to tell their partners// to seek ... or drugs to help reduce infection rates, says a ... an important part of managing most curable sexually transmitted ... often makes this difficult. ,Researchers analysed ...
... is in the process of doing away with a commonly ... phase out the ‘Aropax’ brand of paroxetine and bring in ... used by about 49,000 New Zealanders. ,This move ... maintains that both drugs are the same, except for the ...
... supplements of folic acid could improve the memory and ... researchers from the University of Wageningen gave a group ... acid supplements or a dummy drug for three years, ... ,The folic acid group had significantly better memories and ...
... are helping to lead a large international study // ... in an effort to determine whether exercise really is ... promoted the value of exercise for a variety of ... established as safe in the group of patients who ...
... light of new information on facial transplantation—including the psychological ... of the Royal College of Surgeons of England now ... according to a report published in the Jan. 27 ... in 2003, the Working Party concluded that facial transplantation ...
... It’s no secret why we shed tears. But exactly what our ... ,A new study sheds some light on the complex design ... film, which is made up of three distinct, microscopic layers. The ... when we cry – is sandwiched between a layer of mucus ...
Cached Medicine News:Health News:New International Study to Test Exercise in Heart Failure Patients 2Health News:New International Study to Test Exercise in Heart Failure Patients 3Health News:Royal College Issues Revised Guidelines for Face Transplantation 2Health News:Royal College Issues Revised Guidelines for Face Transplantation 3Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 2Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 3
For the quantitative determination of total cholesterol in human serum....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
Medicine Products: